I Souilem*, I Aouinti, A Zaiem, O Charfi, W Kaabi, S Kastalli, R Daghfous, G Lakhoua and S El Aidli

National Center of Pharmacovigilance, Research Unit: UR17ES12, Faculty of Medicine, University of Tunis El Manar, Tunisia

*Corresponding Author: I Souilem, National Center of Pharmacovigilance, Research Unit: UR17ES12, Faculty of Medicine, University of Tunis El Manar, Tunisia.

Received: May 29, 2023 Published: June 14, 2023

Abstract

Acenocoumarol is the most widely prescribed vitamin K antagonist (VKA) to prevent and treat thromboembolic disorders. It keeps a major place in many indications despite the introduction of new direct oral anticoagulants (DOACs). However, a narrow therapeutic range, an intra-individual variability and drug interactions may lead to serious adverse drug reactions. Sometimes, a genetic or acquired resistance to this drug may lead to a risky situation. Hopefully, resistance to acenocoumarol is a very rare phenomen.

Here in we present an unsusual case of a suspected resistance to acenocoumarol. This case was notified to the Tunisian National Center of Pharmacovigilance on October 2017 and registered under the number 2449/2017.

A 67-year-old patient with hypertension, diabetes, and coronary disease was treated with captopril, atenolol, atorvastatin, and salicylic acid. In 2017, acenocoumarol treatment was introduced. At biological control, the prothrombin time (PT) was 100%. The doses of acenocoumarol were raised progressively with iterative controls of PT. PT was always 100% even when acenocoumarol reached the dose of 2 g/day. A resistance to acenocoumarol was suspected. The patient was referred to pharmacovigilance department for case analysis. During the patient interview, we discover that the patient was confusing acenocoumarol with atenolol. In fact, when his doctor was increasing the doses of acenocoumarol, the patient increased her intake of atenolol believing that it was acenocoumarol.

A resistance to acenocoumarol was eliminated in this patient since she had never taken the drug. We highlight through this case the importance of patient’s interview. Explaining the indications and the potential adverse events of the drug to patients taking VKA is crucial to ensure a better efficiency of treatment without increasing the risk of bleeding complication.

 Keywords: Vitamin K Antagonist; Anticoagulant; Acenocoumarol; Resistance; Pharmacovigilance

References

1. Miremont-Salamé G., et al. “Causality assessment in pharmacovigilance: The French method and its successive updates”. Therapies 71 (2016): 179‑186.
2. Montastruc JL. “Pharmacovigilance and drug safety: Fair prescribing and clinical research”. Therapies 77 (2022): 261‑263.
3. Newman DH and Zhitomirsky I. “The Prevalence of Nontherapeutic and Dangerous International Normalized Ratios Among Patients Receiving Warfarin in the Emergency Department”. Annals of Emergency Medicine 48 (2006): 182-189.e1.
4. McCabe PJ., et al. “Knowledge and self-management behaviors of patients with recently detected atrial fibrillation”. Heart Lung 37 (2008): 79‑90.
5. Palareti G., et al. “Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)”. The Lancet 348 (1996): 423‑428.
6. Kagansky N., et al. “Safety of Anticoagulation Therapy in Well-informed Older Patients”. Archives of Internal Medicine 164 (2004): 2044.
7. Jeddou KB., et al. “Evaluation of anticoagulant therapy management in a teaching hospital in Tunisia: information and education for vitamin k antagonist newly treated patients need to be improved”. International Journal of Pharmacy Practice 29 (2021): 389‑393.
8. Batisse A and Helft G. “Résistance aux anticoagulants oraux - Resistance to anticoagulants”. MISE AU POINT.
9. Wolff FA de and Cate JW ten. “Transient Acquired Resistance to the Coumarin Anticoagulants Phenprocoumon and Acenocoumarol”. Scandinavian Journal of Haematology 23 (2009): 437‑441.

Citation

Citation: I Souilem., et al. “A Mysterious Resistance to Acenocoumarol!". Acta Scientific Pharmacology 4.2 (2023): 01-03.

Copyright

Copyright: © 2023 I Souilem., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.